Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Langdon

Showing results (161-170 of 180) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 1995
Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancerH Gabra, S P Langdon, J E Watson, et al.
British Journal of Cancer|June 1, 1991
Characterisation and properties of a small cell lung cancer cell line and xenograft WX322 with marked sensitivity to alpha-interferonS P Langdon, G J Rabiasz, L Anderson, et al.
British Journal of Cancer|May 3, 2012
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancerA H Sims, A J M Zweemer, Y Nagumo, et al.
Radiation Oncology (London, England)|April 17, 2019
Development and characterisation of acquired radioresistant breast cancer cell linesMark Gray, Arran K Turnbull, Carol Ward, et al.
Cancer Research|November 1, 1988
Characterization and properties of nine human ovarian adenocarcinoma cell linesS P Langdon, S S Lawrie, F G Hay, et al.
Breast Cancer Research : BCR|June 24, 2010
Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancerKaren J Taylor, Andrew H Sims, Liang Liang, et al.
Journal of Biomedical Materials Research. Part B, Applied Biomaterials|October 28, 2018
Biocompatibility of common implantable sensor materials in a tumor xenograft modelMark E Gray, James Meehan, Ewen O Blair, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2011
Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategiesDana Faratian, Annelien J M Zweemer, Yoko Nagumo, et al.
Frontiers in Oncology|May 12, 2020
Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast CancerJames Meehan, Mark Gray, Carlos Martínez-Pérez, et al.
British Journal of Cancer|March 31, 1999
Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868B J Simpson, J M Bartlett, K G Macleod, et al.
Pageof 18

Showing results (161-170 of 180) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 1995
Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancerH Gabra, S P Langdon, J E Watson, et al.
British Journal of Cancer|June 1, 1991
Characterisation and properties of a small cell lung cancer cell line and xenograft WX322 with marked sensitivity to alpha-interferonS P Langdon, G J Rabiasz, L Anderson, et al.
British Journal of Cancer|May 3, 2012
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancerA H Sims, A J M Zweemer, Y Nagumo, et al.
Radiation Oncology (London, England)|April 17, 2019
Development and characterisation of acquired radioresistant breast cancer cell linesMark Gray, Arran K Turnbull, Carol Ward, et al.
Cancer Research|November 1, 1988
Characterization and properties of nine human ovarian adenocarcinoma cell linesS P Langdon, S S Lawrie, F G Hay, et al.
Breast Cancer Research : BCR|June 24, 2010
Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancerKaren J Taylor, Andrew H Sims, Liang Liang, et al.
Journal of Biomedical Materials Research. Part B, Applied Biomaterials|October 28, 2018
Biocompatibility of common implantable sensor materials in a tumor xenograft modelMark E Gray, James Meehan, Ewen O Blair, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2011
Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategiesDana Faratian, Annelien J M Zweemer, Yoko Nagumo, et al.
Frontiers in Oncology|May 12, 2020
Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast CancerJames Meehan, Mark Gray, Carlos Martínez-Pérez, et al.
British Journal of Cancer|March 31, 1999
Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868B J Simpson, J M Bartlett, K G Macleod, et al.
Pageof 18